AstraZeneca Educational Webinar Series
Presented by AADE in association with AstraZeneca-US Medical Affairs, CVMD Division
This educational webinar series is designed to provide the most up-to-date, cutting edge information in diabetes. Each webinar will be presented live and recorded. Archived presentations will be posted on this page for up to 60 days after the live broadcast, so don't miss out!
This webinar series is educational in nature and contains no promotional or product information. CE credit is not available for this activity.
Webinar Schedule for 2019:
All webinars will be held from 1:00-2:00 pm EST
February 13: 2019 Updates on Guidelines in the Management of T2D: Navigating CVOTs and Implications for Treatment
April 10: Cardio-Renal Complications of T2DM: Focus on Heart Failure
June 26: Diabetic Kidney Disease: New Promise for Patients Fighting a Stubborn Nemesis?
August 28: Making Sense of the CVOT Landscape in Type 2 Diabetes
October 23: The Role of the Platelet in Type 2 Diabetes Mellitus: Therapeutic Options (Register now! www.diabeteseducator.org/event/webi191023)
December 4: CVOT Update #2 - SGLT-2 Inhibitors in Type 1 and Type 2 Diabetes
Making Sense of the CVOT Landscape in Type 2 Diabetes
Originally presented on August 28, 2019 by James Ruggles, PhD, and Curtis Triplitt, PharmD, CDE
This presentation aims to put the SGLT-2 Inhibitor and GLP-1 Receptor Agonist CVOTs into context. We'll review study designs, patient populations, and outcomes in patients with established cardiovascular disease and in patients with risk factors.
Upon completion of this activity, participants will be able to:
- Understand key elements in how CVOTs were designed, including key differences in patient populations and treatment duration.
- Understand post-hoc attempts to understand effects in patients with established disease and in patients with risk factors.
- Describe key takeaways and how these results are impacting treatment guidelines and future directions of research.
The Role of the Platelet in Type 2 Diabetes Mellitus: Therapeutic Options
Wednesday, October 23, 2019 at 1:00 pm EST
Presented by Narinder P. Bhalla, MD, FACC, FSCAI and Curtis Triplitt, PharmD, CDE
The program will go over the role of the platelets in patients with T2D and the abnormal physiology of the platelets in this patient group. We will discuss how this abnormal physiology relates to the overall CV risk in patients with Type 2 Diabetes. The data on current approved treatments will be discussed as well as some more recent data.
Upon completion of this activity, participants will be able to:
- Gain knowledge on the abnormal physiology of platelets in this patient group
- Understand the relation of abnormal platelet physiology to cardiovascular risk
- Understand the available therapeutics and newer data in this area
Register now! www.diabeteseducator.org/event/webi191023
CVOT Update #2 - SGLT-2 Inhibitors in Type 1 and Type 2 Diabetes
Wednesday, December 4, 2019 at 1:00 pm EST